

Inhibitory Effects of Ginsenoside Rb₁ on Atopic Dermatitis-Like Skin Lesions in Mice

Hye-Jin Park, Hye-Eun Byeon, Ko Woon Choi, Dong-Kwon Rhee, Kang Ro Lee, and Suhkneung Pyo*

Division of Immunopharmacology, Sungkyunkwan University School of Pharmacy, Suwon 440-746, Korea

Allergies are immediate hypersensitive responses to antigens and interleukin (IL)-4 is involved in the initiation and development of allergic responses. Rb₁ has been known to have a variety of biological activities including anti-inflammatory activity, but the effect of Rb₁ on allergic responses is not known yet. The present study was undertaken to examine whether Rb₁ has an inhibitory effect on allergic response in mouse model. In allergic mouse model, our results showed that topical application of Rb₁ on atopic dermatitis (AD)-like skin lesions improved skin condition and inhibited scratching behaviors. In addition, Rb₁ application not only suppressed mRNA expression of IL-4 and IL-10, but also prevented the nuclear factor of activated T cells 1 transcription. Moreover, Rb₁ application suppressed IL-4's secretion. Taken together, these results suggest that Rb₁ has a potent inhibitory effect in AD-related T cell cytokine production and may be a candidate for therapeutic agent in allergy.

Keywords: Ginsenoside Rb₁, Atopic dermatitis, Scratching behaviors, Interleukin-4

INTRODUCTION

Atopic dermatitis (AD) is a chronic inflammatory skin disease accompanied by several common symptoms including erythema, eczema, and pruritus [1]. In AD, skin becomes extremely itchy followed by severe scratching behavior that induces the production of proinflammatory cytokines. This in turn activates immune cells and initiates inflammatory cycle of AD that accompanied by erythema, keratosis and its scaling. All these symptoms are the consequence of an imbalanced immune response to various allergens [2]. Another defining characteristic of the atopic immune system is the capacity to generate elevated IgE antibodies and type 2 helper T cells (T_H2) are critical for IgE synthesis. T_H2 cells predominantly produce interleukin (IL)-4, IL-5, IL-10, and IL-13, and these cytokines are associated with specific function of immune cells in AD. For example, they act as excel-

lent helpers for B cell activation, particularly antibody responses [3-5]. IL-4, mainly produced by activated T cell, plays a prominent role in immune responses. It also works as the most important determinant of IgE isotype switching in B cell, which in turn elicits allergic immune response, and induces differentiation of naïve CD4 T cells into T_H2 cells [6,7]. Expression of IL-4 appears to be regulated at the transcriptional level and the nuclear factor of activated T cells (NFAT) has been suggested as a transcriptional activator of cytokine genes [8,9].

Red ginseng (*Panax ginseng* C.A. Meyer Radix Rubra) has been most widely used for a long time to enhance immune function as well as stamina, and it has been reported that ginseng has pharmacological effects on the cardiovascular, endocrine, and central nervous systems [10]. Among the components of ginseng,

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received 30 Sep. 2010, Revised 13 Oct. 2010, Accepted 15 Oct. 2010

*Corresponding author

E-mail: snpyo@skku.edu

Tel: +82-31-290-7713, Fax: +82-31-290-7733

ginsenosides appear to be responsible for most of its pharmacological activities. More than 40 ginsenosides have been identified and each ginsenoside may have different biological effect for structural difference. Rb₁, Rb₂, Rg₁, Rg₃, and Rh₂ are the most commonly studied ginsenosides in research and hundreds papers have been reported that ginsenosides show various biological activities including anti-inflammatory, anti-allergic, and anti-tumor activities [11-13]. However, anti-atopic effect of Rb₁ *in vivo* has not been thoroughly studied. The aim of the present study therefore was to determine whether topical application of Rb₁ has inhibitory effects on AD-like skin lesions in animal model.

MATERIALS AND METHODS

Animals and reagents

Six-week-old male BALB/c mice were obtained from the Daehan Biolink Co. (Eumseong, Korea) and housed with free access to food as well as water *ad libitum*. During the experimental period, All animals were maintained at a temperature of 23±1°C, a humidity of 55±5% with 10 to 18 circulation/hour under 12 hours light/dark cycle. The animals were randomly divided into five groups with 5 mice. Group 1, normal control group; group 2, vehicle-treated group; group 3, dexamethasone-treated group; and group 4 and 5, Rb₁-treated groups. All reagents including Rb₁ were purchased from the Sigma-Aldrich Co. (St Louis, MO, USA) unless otherwise stated. The chemical structure of Rb₁ was shown in Fig. 1.

Induction and treatment of atopic dermatitis-like skin lesions in mice

1-chloro-2,4-dinitrobenzene (DNCB) was used as an

inducer of AD. Induction of AD-like skin lesions was performed according to the method of Kim *et al.* [14] with modification. Briefly, 1% of DNCB was freshly dissolved in acetone:olive oil (4:1) and topically applied on the shaved area of dorsal surface twice for a week, and 0.2% of DNCB was then applied in a same way (four times in total). After inducing AD-like skin lesions, skin lesions were treated with Dulbecco's phosphate buffered saline vehicle, dexamethasone (positive control), or Rb₁ (50 and 100 µg/mL) every other day (four times in total). The concentrations of Rb₁ were selected based on previous reports [15]. To compare the improvement of skin condition by treatment with each compound, pictures were taken before and after the treatment.

Measurement of scratching behavior frequency

Scratching behavior was observed after completion of all treatments. In brief, the mice were placed into cages and the number of scratching behaviors was counted for 10 minutes. Measurement was repeated for five times (50 minutes in total). The scratching behavior was defined as the movement with hind paws in this experiment.

Determination of interleukin-4 secretion

The spleens were aseptically removed and total splenocytes were prepared. Splenocytes (5×10⁵ cells/well) were plated at 96-well plates and incubated for 24 hours in RPMI 1640 medium (GIBCO, Grand Island, NY, USA) containing 10% of FBS (Hyclone, Logan, UT, USA), penicillin (100 U/mL), and streptomycin (100 µg/mL) at 37°C in a 5% CO₂ humidified incubator. Culture supernatants were collected and the amount of secreted IL-4 was measured using enzyme-linked immunoassay kit purchased from Biolegend, Inc. (San Diego, CA, USA).

Measurement of serum IgE level

Blood samples were collected from the inferior vena cava after finishing treatment and serum was separated. The serum concentration of IgE was measured by enzyme-linked immunoassay kit purchased from Biolegend, Inc.

RT-PCR analysis of gene expression

The expression of mRNA transcripts of IL-4, IL-10 and NFAT was determined by reverse transcriptase-polymerase chain reaction. Total RNA was extracted from splenocytes using the Trizol (Invitrogen, Carlsbad, CA, USA) reagent and processed to cDNA with RevertAid (Fermentas, Vilnius, Lithuania). Solgent™ EF-Taq DNA Polymerase kit (Solgent Co., Daejeon, Korea) was




Fig. 1. Chemical structure of ginsenoside Rb₁.

Table 1. Primers for reverse transcriptase PCR

Genes	Sequence of forward and reverse primers
Interleukin -4	Forward: 5'-ATGGGTCTCAACCCCGAGCTAGT-3 Reverse: 5'-GCTCTTTACGCTTCCAGGAAGTC-3
Interleukin-10	Forward: 5'-CTGCTCTTACTGACTGGCATGAG-3 Reverse: 5'-GACTCAATACACACTGCAGGTGT-3
NFATc2(NFAT1)	Forward: 5'-TGGCCCGCGACATCTACCCT-3 Reverse: 5'-TGGTAGAAGGCGTGCGGCTT-3
GAPDH	Forward: 5'-CCATGGAGAAGGCTGGGG-3 Reverse: 5'-CCAAGTTGTCATGGATGACC-3

NFAT, nuclear factor of activated T cells.

used for PCR analysis and cDNA was amplified using primers as shown in Table 1. PCR conditions were as follows: 94°C 30 seconds, 58°C 45 seconds, and 72°C 30 seconds repeated 32 times for IL-4; 94°C 1 minute, 65°C 2 minutes, and 72°C 1 minute repeated 40 times for IL-10; 95°C 25 seconds, 54°C 30 seconds, and 68°C 45 seconds repeated 31 times for NFAT1; 92°C 30 seconds, 58°C 30 seconds, and 72°C 1 minute repeated 25 times for GAPDH.

RESULTS

Effect of Rb₁ on atopic dermatitis-like skin lesions

AD-like skin lesions were induced in BALB/c mice by topical application of DNCB compared to untreated group (Fig. 2A). After the first application of DNCB, erythema began to appear on the back followed by eczema

and keratosis with final application (Fig. 2B-E). In contrast, treatment of AD-like skin lesions with Rb₁ resulted in improved skin condition (Fig. 2I and 2J) as compared to the DNCB-treated group (Fig. 2G). We also examined the inhibitory effect of dexamethasone, a well-known anti-inflammatory and immunosuppressant. As shown in Fig. 2B, dexamethasone significantly reduced DNCB-induced AD-like skin lesions. Based on these findings, Rb₁ may have activities similar to dexamethasone.

Effect of Rb₁ on scratching behavior frequency

To investigate the antiatopic effect of Rb₁, we examined the effect Rb₁ on scratching behavior, a typical clinical symptom of AD. DNCB application caused a substantial increase in the frequency of scratching behavior. However, Rb₁ treatment significantly suppressed DNCB-mediated scratching behavior (Fig. 3), although its inhibitory effect was less significant than dexamethasone, a type of steroid drug used to treat many inflammatory diseases.

Effect of Rb₁ on interleukin-4 secretion

Overexpression of IL-4 is associated with allergic response. To further investigate the mechanism of action of Rb₁, we examined the effect Rb₁ on IL-4 secretion. As shown in Fig. 4, DNCB-induced AD mice showed much higher level of secreted IL-4 than that of control mice,




Fig. 2. Atopic dermatitis (AD)-like skin lesions and improvement of skin condition after treatment with Rb₁. AD-like skin lesions were induced by topical application of 1-chloro-2,4-dinitrobenzene (DNCB) for 4 times (B-E), and Rb₁ application on the skin lesions improved the skin condition (G, treatment with PBS; H, treatment with dexamethasone; I, treatment with 50 µg/mL of Rb₁; J, treatment with 100 µg/mL of Rb₁). Dex, dexamethasone.




Fig. 3. Inhibitory effect of Rb₁ on 1-chloro-2,4-dinitrobenzene (DNCB)-induced scratching behaviors. Scratching behavior was observed after completion of all treatments. In brief, the number of scratching behaviors was counted for 10 minutes. Measurement was repeated for five times (50 minutes in total). Dex, dexamethasone. *Significantly different from DNCB-treated group ($p < 0.05$).




Fig. 4. Inhibitory effect of Rb₁ on 1-chloro-2,4-dinitrobenzene (DNCB)-induced IL-4 secretion in splenocytes. After completion of all treatments, splenocytes (5×10^5 cells/well) were incubated for 24 hours. Culture supernatants were collected and level of secreted IL-4 was determined using ELISA. The data are presented as the mean \pm SD of a representative experiment of triplicates. Dex, dexamethasone. *Significantly different from DNCB-treated group ($p < 0.05$).

while Rb₁ treatment suppressed secretion of IL-4 and Rb₁ appears to be more effective than dexamethasone on suppression of IL-4 secretion.

Effect of Rb₁ on mRNA levels of cytokines and NFAT1

To determine whether Rb₁ might be involved in cytokine gene regulation, the levels of IL-4 and IL-10 mRNA expression on splenocytes were examined by RT-PCR analysis. DNCB significantly induced mRNA levels of both IL-4 and IL-10. When DNCB-induced AD mice were treated with 100 μ g/mL of Rb₁ four times, Rb₁ suppressed DNCB-induced mRNA levels of IL-4 as well as IL-10 (Fig. 5A). The effect of Rb₁ on mRNA level of NFAT1, which is known to induce various cytokine genes including IL-4, was also examined. Consistent with mRNA levels of cytokines, Rb₁ treatment resulted in decrease of NFAT1 expression (Fig. 5 B).

Effect of Rb₁ on serum IgE level

High level of IgE in the blood is a clear indicator of AD. Therefore, we examined whether Rb₁ can suppress serum IgE in AD mice. Although dexamethasone decreased DNCB-induced IgE in serum, Rb₁ treatment did not suppress (Fig. 6).

DISCUSSION

In the present study, we examined the effect of Rb₁ on AD-like skin lesions in mice. Skin sensitivity and inflammation induced by DNCB have been known to be characterized by raised IgE and cytokines such as IL-4 and IL-10 [14,16]. The results of this study demonstrate that topically applied ginsenoside Rb₁ exerts beneficial effects in mouse model of AD.

In atopic dermatitis, skin lesions were characterized by infiltration of IL-4 producing CD4⁺ T cells, indicating that IL-4 is likely to play a major role in AD since it me-




Fig. 5. Suppressive effect of Rb₁ on mRNA expressions of IL-4, IL-10, and the nuclear factor of activated T cells (NFAT) 1. After completion of all treatments, total RNA was extracted from splenocytes. RT-PCR analysis was performed to measure mRNA levels of IL-4, IL-10, and NFAT1, respectively. The results illustrated are from a single experiment, and are representative of three separate experiments. DNCB, 1-chloro-2,4-dinitrobenzene; Dex, dexamethasone.




Fig. 6. Effect of Rb₁ on level of IgE in serum. After completion of all treatments, blood samples were collected from the inferior vena cava and serum was separated. Level of serum IgE was measured by ELISA. The data are presented as the mean±SD of a representative experiment of triplicates. *Significantly different from DNCB-treated group ($p<0.05$).

diates Ig isotype switching from IgM to IgE [6,7]. In addition, IL-10 plays an important role in the T_H2 response in a murine model of allergic dermatitis [17]. It has been also known that the upregulation of total serum IgE is a hallmark of AD [18]. Our data showed that the expression of IL-4 and IL-10 increased in the splenocytes from the control mice developing skin lesions was suppressed by Rb₁ treatment. However, although the application of Rb₁ significantly reduced the severities of AD-like skin lesions induced by DNCB, it did not inhibit total serum IgE levels. For many years there has been an argument for the contribution of IgE-mediated hypersensitivity reactions in the pathogenesis of AD [19], because in some chronic AD skin lesions the development of AD appears to be independent of plasma IgE levels. Moreover, it has recently been suggested that increased IgE production and subsequent IgE-mediated hypersensitivity reactions may not contribute to the development of the AD-like skin lesions observed in NC/Nga mouse model [20]. Therefore, the results of this study do not support the notion that IgE plays a role in modulating AD-like lesions induced by DNCB and might provide an extended scope to the prevailing concept of IgE-independent mechanism underlying the pathobiology of AD.

T_H2 cells produce IL-4, IL-5, and IL-10, and are involved in humoral immunity and the allergic response. Our results demonstrated that Rb₁ inhibited DNCB-induced transcript levels for the cytokines. This suggests that Rb₁ may inhibit the expression of cytokines by interfering with the transcription of their respective genes. It may inhibit either the initiation of transcription or the stability of the mRNAs encoding these molecules. It has

been also shown that activation of transcription factor NFAT is required for the transcriptional activation of cytokines [8,9], suggesting that NFAT appears to play a pivotal role in IL-4 and IL-10 gene activation. Therefore, the decreased expression of IL-4 and IL-10 prompted us to examine the effect of Rb₁ on NFAT implicated in the regulation of a variety of genes participating in immune responses, including genes encoding IL-4 and IL-10. The present data showed that Rb₁ inhibited DNCB-induced NFAT activation. However, our results do not eliminate the possible involvement of alternative transcription factors, because STAT6 and c-Maf are known to be involved in gene expression of these cytokines [21-23]. It is, therefore, possible that inhibitory effect of Rb₁ on cytokine expression may be at least partially mediated through suppression of the NFAT transcription factor.

In summary, the application of ginsenoside Rb₁ was found to inhibit the development of AD-like skin lesions induced by DNCB. In addition, the results of the present study demonstrate that Rb₁ is capable of inhibiting the expression of cytokines, which results from the suppression of NFAT activation in splenocytes. Thus, Rb₁ is proposed as an effective new anti-inflammatory agent that may have a potential therapeutic use for preventing the advancement of atopic dermatitis.

REFERENCES

1. Joo SS, Kim SG, Choi SE, Kim YB, Park HY, Seo SJ, Choi YW, Lee MW, Lee DI. Suppression of T cell activation by hirsutenone, isolated from the bark of *Alnus japonica*, and its therapeutic advantages for atopic dermatitis. *Eur J Pharmacol* 2009;614:98-105.
2. Furrie E. Probiotics and allergy. *Proc Nutr Soc* 2005;64:465-469.
3. Maggi E, Del Prete G, Macchia D, Parronchi P, Tiri A, Chrétien I, Ricci M, Romagnani S. Profiles of lymphokine activities and helper function for IgE in human T cell clones. *Eur J Immunol* 1988;18:1045-1050.
4. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 1989;7:145-173.
5. Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. *Int J Clin Lab Res* 1991;21:152-158.
6. Yoshimoto T, Mizutani H, Tsutsui H, Noben-Trauth N, Yamanaka K, Tanaka M, Izumi S, Okamura H, Paul WE, Nakanishi K. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. *Nat Immunol* 2000;1:132-

137.

7. Park J, Chung SW, Kim SH, Kim TS. Up-regulation of interleukin-4 production via NF-AT/AP-1 activation in T cells by biochanin A, a phytoestrogen and its metabolites. *Toxicol Appl Pharmacol* 2006;212:188-199.
8. Cron RQ, Bort SJ, Wang Y, Brunvand MW, Lewis DB. T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. *J Immunol* 1999;162:860-870.
9. Luo C, Burgeon E, Carew JA, McCaffrey PG, Badalian TM, Lane WS, Hogan PG, Rao A. Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes. *Mol Cell Biol* 1996;16:3955-3966.
10. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. *Biochem Pharmacol* 1999;58:1685-1693.
11. Lü JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. *Curr Vasc Pharmacol* 2009;7:293-302.
12. Park EK, Choo MK, Han MJ, Kim DH. Ginsenoside Rh1 possesses antiallergic and anti-inflammatory activities. *Int Arch Allergy Immunol* 2004;133:113-120.
13. Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, Kudoh K, Nagata I, Shinomiya N. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. *Jpn J Cancer Res* 1998;89:733-740.
14. Yun JW, Kim H, Kang HJ, Koh JY, Kim BH. Comparative evaluation of animal models for atopic dermatitis in NC/Nga mice. *Lab Anim Res* 2008;24:59-66.
15. Lee HU, Bae EA, Han MJ, Kim NJ, Kim DH. Hepatoprotective effect of ginsenoside Rb1 and compound K on tert-butyl hydroperoxide-induced liver injury. *Liver Int* 2005;25:1069-1073.
16. Izuhara K, Yanagihara Y, Hamasaki N, Shirakawa T, Hopkin JM. Atopy and the human IL-4 receptor alpha chain. *J Allergy Clin Immunol* 2000;106(1 Pt 2):S65-S71.
17. Laouini D, Alenius H, Bryce P, Oettgen H, Tsitsikov E, Geha RS. IL-10 is critical for Th2 responses in a murine model of allergic dermatitis. *J Clin Invest* 2003;112:1058-1066.
18. Lester MR, Hofer MF, Gately M, Trumble A, Leung DY. Down-regulating effects of IL-4 and IL-10 on the IFN-gamma response in atopic dermatitis. *J Immunol* 1995;154:6174-6181.
19. Blumenthal MN. The role of genetics in the development of asthma and atopy. *Curr Opin Allergy Clin Immunol* 2005;5:141-145.
20. Halbert AR, Weston WL, Morelli JG. Atopic dermatitis: is it an allergic disease? *J Am Acad Dermatol* 1995;33:1008-1018.
21. Yagi R, Nagai H, Iigo Y, Akimoto T, Arai T, Kubo M. Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice. *J Immunol* 2002;168:2020-2027.
22. Lim CP, Cao X. Structure, function, and regulation of STAT proteins. *Mol Biosyst* 2006;2:536-550.
23. Cao S, Liu J, Song L, Ma X. The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. *J Immunol* 2005;174:3484-3492.